Icatibant Aguettant (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms driving swelling in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The prescriber will specify the exact amount and frequency for each individual.

Safety data for icatibant in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑esterase inhibitor concentrates act by replacing deficient proteins. Icatibant offers a rapid, subcutaneous route of administration and is particularly useful for patients who prefer self‑injection or have limited access to intravenous infusions.

Icatibant should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until ready for use to maintain stability.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and laryngeal or systemic angioedema that can compromise breathing. Patients should be monitored closely after the first dose and instructed to seek immediate medical attention if any of these symptoms occur.

Icatibant is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with uncontrolled cardiovascular disease or those taking medications that significantly increase bradykinin levels should discuss suitability with their physician.